Achilles Therapeutics (“Achilles”), a clinical-stage oncology company developing personalised cell therapies targeting clonal neoantigens, a novel class of tumour target, today announced that it will present a manufacturing update using the VELOSTM manufacturing platform for its lead programs at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting.
“This study using our VELOSTM manufacturing platform demonstrates the feasibility of generating clonal neoantigen T cells, or cNeT, for the treatment of NSCLC and recurrent or metastatic melanoma,” said Ed Samuel, SVP Manufacturing, Achilles Therapeutics. “Achilles is at a transformational stage in its development as we progress our two lead products into the clinic. We have prioritised our scaled GMP manufacturing platform from the inception of the Company in order to support our long-term strategy to develop a fully closed and automated manufacturing process which is central to our plans for scaling up production capabilities to deliver personalized cell therapies to patients.”
Oral Presentation details:
The virtual meeting is free and available to anyone by registering at aacr.org.
|
Presentation Title: |
The development of a personalised autologous clonal neoantigen T cell therapy for the treatment of solid cancer using the VELOSTM manufacturing platform generates highly potent and reactive CD8+ and CD4+ T cells for clinical use |
|
Presenter: |
Ed Samuel |
|
Session Title: |
VCTPL05 – Adoptive Cell Transfer Therapy |
|
Date and Presentation Time: |
April 28, 2020 - 11:55 - 12:05 PM EDT |
|
Abstract Number: |
CT054 |
- Ends -